Suppr超能文献

COVID-19 患者可能易患肺动脉高压。

COVID-19 patients may become predisposed to pulmonary arterial hypertension.

机构信息

Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA.

Department of Pathological Anatomy N2, Bogomolets National Medical University, Kyiv 01601, Ukraine.

出版信息

Med Hypotheses. 2021 Feb;147:110483. doi: 10.1016/j.mehy.2021.110483. Epub 2021 Jan 6.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the current pandemic of coronavirus disease 2019 (COVID-19) that have killed over one million people worldwide so far. To date, over forty million people have officially been identified to be infected with this virus with less than 3% death rate. Since many more people are expected to have been infected with this virus without the official diagnosis, the number of people who have recovered from the SARS-CoV-2 infection should be substantial. Given the large number of people recovered from either the mild SARS-CoV-2 infection or more severe COVID-19 conditions, it is critical to understand the long-term consequences of the infection by this virus. Our histological evaluations revealed that patients died of COVID-19 exhibited thickened pulmonary vascular walls, one important hallmark of pulmonary arterial hypertension (PAH). By contrast, such pulmonary vascular remodeling lesions were not found in patients died of SARS-CoV-1 during the 2002-2004 SARS outbreak or due to the infection by H1N1 influenza. The advancement in the treatment for the human immunodeficiency virus (HIV) infection has been remarkable that HIV-infected individuals now live for a long time, in turn revealing that these individuals become susceptible to developing PAH, a fatal condition. We herein hypothesize that SARS-CoV-2 is another virus that is capable to triggering the increased susceptibility of infected individuals to developing PAH in the future. Given the large number of people being infected with SARS-CoV-2 during this pandemic and that most people recover from severe, mild or asymptomatic conditions, it is imperative to generate scientific information on how the health of recovered individuals may be affected long-term. PAH is one lethal consequence that should be considered and needs to be monitored. This may also foster the research on developing therapeutic agents to prevent PAH, which has not so far been successful.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)正在引发当前的 2019 年冠状病毒病(COVID-19)大流行,迄今为止,全球已有超过 100 万人因此死亡。截至目前,已有超过 4000 万人被正式确认为感染该病毒,死亡率不到 3%。由于预计还有更多的人感染了这种病毒而没有得到官方诊断,因此从 SARS-CoV-2 感染中康复的人数应该相当多。鉴于从轻度 SARS-CoV-2 感染或更严重的 COVID-19 中康复的人数众多,了解该病毒感染的长期后果至关重要。我们的组织学评估表明,死于 COVID-19 的患者表现出肺血管壁增厚,这是肺动脉高压(PAH)的一个重要标志。相比之下,在 2002-2004 年 SARS 爆发期间或由于感染 H1N1 流感而死于 SARS-CoV-1 的患者中,并未发现这种肺血管重塑病变。人类免疫缺陷病毒(HIV)感染的治疗进展显著,HIV 感染者现在可以长期存活,这反过来又表明这些个体易患致命的 PAH。我们在此假设,SARS-CoV-2 是另一种能够在未来引发感染个体易患 PAH 的病毒。鉴于在此大流行期间有大量人感染 SARS-CoV-2,并且大多数人从严重、轻度或无症状的情况下康复,因此必须生成有关康复个体的健康状况可能长期受到影响的科学信息。PAH 是一种应考虑并需要监测的致命后果。这也可能促进开发预防 PAH 的治疗药物的研究,迄今为止,这方面的研究尚未成功。

相似文献

1
COVID-19 patients may become predisposed to pulmonary arterial hypertension.
Med Hypotheses. 2021 Feb;147:110483. doi: 10.1016/j.mehy.2021.110483. Epub 2021 Jan 6.
5
Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection.
Microb Pathog. 2021 Mar;152:104554. doi: 10.1016/j.micpath.2020.104554. Epub 2020 Nov 3.
6
The Outcome of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension during the COVID-19 Pandemic.
Crit Pathw Cardiol. 2023 Jun 1;22(2):60-64. doi: 10.1097/HPC.0000000000000317. Epub 2023 Mar 23.
8
From acute SARS-CoV-2 infection to pulmonary hypertension.
Front Physiol. 2022 Dec 19;13:1023758. doi: 10.3389/fphys.2022.1023758. eCollection 2022.
9
Comparison of patients hospitalized with COVID-19, H7N9 and H1N1.
Infect Dis Poverty. 2020 Dec 2;9(1):163. doi: 10.1186/s40249-020-00781-5.

引用本文的文献

1
Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension.
Am J Physiol Lung Cell Mol Physiol. 2024 Dec 1;327(6):L972-L983. doi: 10.1152/ajplung.00208.2024. Epub 2024 Oct 15.
4
Clinical and echocardiographic findings in patients with COVID-19 across different severity levels.
J Med Life. 2023 Nov;16(11):1692-1700. doi: 10.25122/jml-2023-0206.
7
Beyond Acute COVID-19: A Review of Long-term Cardiovascular Outcomes.
Can J Cardiol. 2023 Jun;39(6):726-740. doi: 10.1016/j.cjca.2023.01.031. Epub 2023 Feb 6.
8
Cardiopulmonary disease as sequelae of long-term COVID-19: Current perspectives and challenges.
Front Med (Lausanne). 2022 Nov 30;9:1041236. doi: 10.3389/fmed.2022.1041236. eCollection 2022.
9
Management of COVID-19 in Patients with Pulmonary Arterial Hypertension.
Heart Fail Clin. 2023 Jan;19(1):107-114. doi: 10.1016/j.hfc.2022.07.003. Epub 2022 Aug 10.
10
Comprehensive Review of Pulmonary Hypertension and Treatment Options in the Paediatric Population.
Cureus. 2022 Oct 23;14(10):e30622. doi: 10.7759/cureus.30622. eCollection 2022 Oct.

本文引用的文献

1
SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells.
Vascul Pharmacol. 2021 Apr;137:106823. doi: 10.1016/j.vph.2020.106823. Epub 2020 Nov 21.
3
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.
Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
5
Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.
Clin Res Cardiol. 2020 May;109(5):531-538. doi: 10.1007/s00392-020-01626-9. Epub 2020 Mar 11.
6
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.
Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.
7
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
8
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
9
Carfilzomib reverses pulmonary arterial hypertension.
Cardiovasc Res. 2016 May 15;110(2):188-99. doi: 10.1093/cvr/cvw047. Epub 2016 Mar 6.
10
Management of pulmonary arterial hypertension.
J Am Coll Cardiol. 2015 May 12;65(18):1976-97. doi: 10.1016/j.jacc.2015.03.540.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验